EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.

Witjes, J.A.; Babjuk, M.; Bellmunt, J.; Bruins, H.M.; De Reijke, T.M.; De Santis, M.; Gillessen, S.; James, N.; Maclennan, S.; Palou, J.; Powles, T.; Ribal, M.J.; Shariat, S.F.; Der Kwast, T.V.; Xylinas, E.; Agarwal, N.; Arends, T.; Bamias, A.; Birtle, A.; Black, P.C.; Bochner, B.H.; Bolla, M.; Boormans, J.L.; Bossi, A.; Briganti, A.; Brummelhuis, I.; Burger, M.; Castellano, D.; Cathomas, R.; Chiti, A.; Choudhury, A.; Compérat, E.; Crabb, S.; Culine, S.; De Bari, B.; De Blok, W.; J L De Visschere, P.; Decaestecker, K.; Dimitropoulos, K.; Dominguez-Escrig, J.L.; Fanti, S.; Fonteyne, V.; Frydenberg, M.; Futterer, J.J.; Gakis, G.; Geavlete, B.; Gontero, P.; Grubmüller, B.; Hafeez, S.; Hansel, D.E.; Hartmann, A.; Hayne, D.; Henry, A.M.; Hernandez, V.; Herr, H.; Herrmann, K.; Hoskin, P.; Huguet, J.; Jereczek-Fossa, B.A.; Jones, R.; Kamat, A.M.; Khoo, V.; Kiltie, A.E.; Krege, S.; Ladoire, S.; Lara, P.C.; Leliveld, A.; Linares-Espinós, E.; Løgager, V.; Lorch, A.; Loriot, Y.; Meijer, R.; Mir, M.C.; Moschini, M.; Mostafid, H.; Müller, A.C.; Müller, C.R.; N'Dow, J.; Necchi, A.; Neuzillet, Y.; Oddens, J.R.; Oldenburg, J.; Osanto, S.; J G Oyen, W.; Pacheco-Figueiredo, L.; Pappot, H.; Patel, M.I.; Pieters, B.R.; Plass, K.; Remzi, M.; Retz, M.; Richenberg, J.; Rink, M.; Roghmann, F.; Rosenberg, J.E.; Rouprêt, M.; Rouvière, O.; Salembier, C.; Salminen, A.; Sargos, P.; Sengupta, S.; Sherif, A.; Smeenk, R.J.; Smits, A.; Stenzl, A.; Thalmann, G.N.; Tombal, B.; Turkbey, B.; Lauridsen, S.V.; Valdagni, R.; Der Heijden, AGV; Van Poppel, H.; Vartolomei, M.D.; Veskimäe, E.; Vilaseca, A.; Rivera, FAV; Wiegel, T.; Wiklund, P.; Williams, A.; Zigeuner, R.; Horwich, A.

doi:10.1016/j.eururo.2019.09.035

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.

Détails

Demande d'une copie

ID Serval

serval:BIB_F039FE6EE179

Type

Article: article d'un périodique ou d'un magazine.

Sous-type

Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.

Collection

Publications

Institution

UNIL/CHUV

Titre

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.

Périodique

European urology

Auteur⸱e⸱s

Witjes J.A., Babjuk M., Bellmunt J., Bruins H.M., De Reijke T.M., De Santis M., Gillessen S., James N., Maclennan S., Palou J., Powles T., Ribal M.J., Shariat S.F., Der Kwast T.V., Xylinas E., Agarwal N., Arends T., Bamias A., Birtle A., Black P.C., Bochner B.H., Bolla M., Boormans J.L., Bossi A., Briganti A., Brummelhuis I., Burger M., Castellano D., Cathomas R., Chiti A., Choudhury A., Compérat E., Crabb S., Culine S., De Bari B., De Blok W., J L De Visschere P., Decaestecker K., Dimitropoulos K., Dominguez-Escrig J.L., Fanti S., Fonteyne V., Frydenberg M., Futterer J.J., Gakis G., Geavlete B., Gontero P., Grubmüller B., Hafeez S., Hansel D.E., Hartmann A., Hayne D., Henry A.M., Hernandez V., Herr H., Herrmann K., Hoskin P., Huguet J., Jereczek-Fossa B.A., Jones R., Kamat A.M., Khoo V., Kiltie A.E., Krege S., Ladoire S., Lara P.C., Leliveld A., Linares-Espinós E., Løgager V., Lorch A., Loriot Y., Meijer R., Mir M.C., Moschini M., Mostafid H., Müller A.C., Müller C.R., N'Dow J., Necchi A., Neuzillet Y., Oddens J.R., Oldenburg J., Osanto S., J G Oyen W., Pacheco-Figueiredo L., Pappot H., Patel M.I., Pieters B.R., Plass K., Remzi M., Retz M., Richenberg J., Rink M., Roghmann F., Rosenberg J.E., Rouprêt M., Rouvière O., Salembier C., Salminen A., Sargos P., Sengupta S., Sherif A., Smeenk R.J., Smits A., Stenzl A., Thalmann G.N., Tombal B., Turkbey B., Lauridsen S.V., Valdagni R., Der Heijden AGV, Van Poppel H., Vartolomei M.D., Veskimäe E., Vilaseca A., Rivera FAV, Wiegel T., Wiklund P., Williams A., Zigeuner R., Horwich A.

ISSN

1873-7560 (Electronic)

ISSN-L

0302-2838

Statut éditorial

Publié

Date de publication

02/2020

Peer-reviewed

Oui

Volume

Numéro

Pages

223-250

Langue

anglais

Notes

Publication types: Journal Article
Publication Status: ppublish

Résumé

Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.
To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.
A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.
Online Delphi survey and consensus conference.
The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.
Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).
Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease.
These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach.
This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Mots-clé

Bladder cancer, Consensus, Delphi, Diagnosis, Follow-up, Treatment

OAI-PMH

oai:serval.unil.ch:BIB_F039FE6EE179

DOI

10.1016/j.eururo.2019.09.035

Pubmed

31753752

Web of science

000507362200017

Open Access

Oui